Bank of America, NA (Private Bank.. recently announced the acquisition of new stake in Adial Pharmaceuticals Inc. (NASDAQ:ADIL). This fresh investment now brings its stake to 1.12% valued currently at $0.24 million. In addition, Renaissance Technologies LLC raised its holdings by 42007.0 to 42007.0 shares.
With over 1.01 million Adial Pharmaceuticals Inc. (ADIL) shares trading Tuesday and a closing price of $1.42 on the day, the dollar volume was approximately $1.43 million. The shares have shown a negative weekly performance of -5.96% and its price on 08/25/20 lost nearly -0.70%. Currently, there are 11.29M common shares owned by the public and among those 10.66M shares have been available to trade.
An analysis of what Wall Street brokers have to say about the expected price targets for this stock gives us this picture: 1 analysts who have offered their price forecasts for ADIL have a consensus price objective of $5.00. The analysts have set the share’s price value over the next 12 months at a high of $5.00 and a low of $5.00 should the stock experience a downside. Incidentally, analysts’ outlook for the Adial Pharmaceuticals Inc. stock is 2.00 for the next 12 months. But an upside of 71.6% will see the stock hit the forecast high price target while mean target price for the stock is $5.00.
Insiders at the company have transacted a total of 9 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 8 of these insider trades were purchases, accounting for 129,082 shares. Insider sales of the common stock occurred on 1 occasions, with total insider shares sold totaling 150,000 shares.
The top 3 mutual fund holders in Adial Pharmaceuticals Inc. are Vanguard Total Stock Market Index, Vanguard Extended Market Index Fu, and Fidelity Extended Market Index Fu. Vanguard Total Stock Market Index owns 0.18 million shares of the company’s stock, all valued at over $0.28 million. Fidelity Extended Market Index Fu now owns shares totaling to 0.34% of the shares outstanding.
Shares of Adial Pharmaceuticals Inc. (NASDAQ: ADIL) opened at $1.40, down -$0.03 from a prior closing price of $1.43. However, the script later closed the day at $1.42, down -0.70%. The company’s stock has a 5-day price change of -5.96% and -16.47% over the past three months. ADIL shares are trading -41.08% year to date (YTD), with the 12-month market performance down to -16.96% lower. It has a 12-month low price of $1.00 and touched a high of $3.17 over the same period. Currently, 1.01 million shares have been traded, compared to an average intraday trading volume of 1.03 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -13.28%, -6.23%, and -11.72% respectively.
Institutional ownership of Adial Pharmaceuticals Inc. (NASDAQ: ADIL) shares accounts for 11.30% of the company’s 11.29M shares outstanding. Mutual fund holders own 2.70%, while other institutional holders and individual stakeholders account for 8.57% and 19.33% respectively.
It has a market capitalization of $19.94M. The earnings-per-share (ttm) stands at -$0.74. Price movements for the stock have been influenced by the stock’s volatility, which stands at 8.60% over the week and 14.94% over the month.
Analysts forecast that Adial Pharmaceuticals Inc. (ADIL) will achieve an EPS of -$0.18 for the current quarter, -$0.19 for the next quarter and -$0.58 for 2021. The lowest estimate earnings-per-share for the quarter is -$0.18 while analysts give the company a high EPS estimate of -$0.18. Comparatively, EPS for the current quarter was -$0.27 a year ago. Earnings per share for the fiscal year are expected to increase by 64.30%, and 23.70% over the next financial year.
If you are looking to buy this stock, then you may note that the average analyst recommendation by 1 brokerage firm advisors rate Adial Pharmaceuticals Inc. (ADIL) as a “Moderate Buy” at a consensus score of 2.00. Specifically, 1 Wall Street analysts polled rate the stock as a buy, while 0 of the 1 advise that investors “hold,” and 0 rated it as a “Sell.”
Looking at the support for the ADIL, a number of firms have released research notes about the stock. Maxim Group stated their Buy rating for the stock in a research note on October 30, 2018, with the firm’s price target at $5. Dawson James coverage for the Adial Pharmaceuticals Inc. (ADIL) stock in a research note released on October 11, 2018 offered a Buy rating with a price target of.